Canadian physician, scholar, and cancer researcher Michael Allen Baker, CM OOnt. He is a professor of medicine at the University of Toronto, the Rose Family Chair in Medicine, and the former Physician-in-Chief of the University Health Network. His work has advanced knowledge of other cancers as well as human leukaemia. Baker, who was born in Toronto, Ontario, went to Oakwood Collegiate Institute before earning his M.D. in 1966 from the University of Toronto. He is a Fellow of the Royal College of Physicians and Surgeons of Canada with a focus in Hematology and Internal Medicine. He graduated from the National Board of Medical Examiners in 1967. He started working as a professor of medicine at the University of Toronto in 1982. He was appointed Physician-in-Chief of Toronto General Hospital in 1992. He was on the board of the Canadian Cancer Society for five years while serving three years as president of the National Cancer Institute of Canada. [2] He was chosen in 2008 to lead the government's patient safety agenda as the Executive Lead - Patient Safety for the Ontario Ministry of Health and Long-Term Care. He was chosen as the Institute of Evaluative Sciences' Board Chair in 2011. (ICES).

Qualification

• C.M.
• O.Ont
• FRCPC

At the Icahn School of Medicine at Mount Sinai in New York City, Christopher E. Walsh, MD, Ph.D., is an Associate Professor and the Program Director for Hemophilia in the Division of Hematology and Medical Oncology. He earned his MD from Tulane University School of Medicine and his Ph.D. in Biochemistry from Wake Forest School of Medicine. At the North Carolina Memorial Hospital in Chapel Hill, he finished an internship and an internal medicine residency, and at the National Institutes of Health in Bethesda, Maryland, he completed an internal medicine residency and a fellowship in haematology. Internal medicine and haematology are both board certified by Dr. Walsh. The HTCs in New England that are sponsored by ATHN are regionally directed by Dr. Walsh. Hemophilia of New York, the Hemophilia Federation of America, the American Thrombosis and Hemostasis Network (ATHN), and NHF MASAC are among the organisations on whose boards he serves. He specialises on fundamental research on gene therapy for blood disorders. He was a pioneer in the study of the Adeno-associated virus and its initial application as a vector for gene therapy. Also, he is working hard to create gene therapies for conditions like von Willebrand disease and haemophilia A and B.

Qualification

• MD
• PhD

At the University of Western Ontario, where he also finished his internal medicine residency, Dr. Christopher Patriquin earned his medical degree. He pursued his haematology fellowship at McMaster University, where he also continued his studies as a Clinical Scholar in complement-mediated illness. His M.Sc. in Health Research Methods concentrated on efficient trial and observational approaches in uncommon diseases. His clinical interests include the thrombotic microangiopathies (TMA) and paroxysmal nocturnal hemoglobinuria (PNH). Dr. Patriquin earned honorary clinical research fellowships in TMA (University College London) and PNH in the United Kingdom in 2015. (NHS National PNH Service, St. James Hospital, Leeds).

Qualification

• MD
• MSc
• FRCPC

Oncologist and haematologist Dr. Sam Berger is considered to be among the best in North York, Ontario. He investigates and makes diagnoses for illnesses and conditions affecting the immune system, bone marrow, and blood as a committed oncologist and haematologist. In order to identify the appropriate course of treatment, he does this by speaking with patients. Also, he advises and prescribes testing to establish the severity of the ailment, aiding in the diagnosis.

Qualification

• MD
• FRCPC

Qualification

• MD

Gerald Batist is the director of the McGill Centre for Translational Research in Cancer and the former chair of the department of oncology at McGill University. The Segal Cancer Centre at the Jewish General Hospital, which he also oversees, expanded after receiving a significant grant from the Canadian Fund for Innovation. Despite attending college in New York City, Dr. Gerald Batist returned to Montreal to attend McGill University for medical school. Post-doctoral training then took place in New York, Boston, and eventually at the National Cancer Institute in Washington. He received his training in molecular pharmacology and medical oncology there. Dr. Batist is a clinician-scientist with molecular pharmacology and medical oncology training. His research in both the clinic and in the lab focuses on treatment resistance. This includes sizable consortiums that conduct extensive biopsy-based clinical trials to find brand-new medication resistance mechanisms. He co-directed a successful application in 2014 that led to the creation of Exactis Innovations, the Canadian National Centre of Excellence in Personalized Medicine. The main component is a project dubbed ""Personalize My Treatment"" that aims to create a sizable biobank and database linked to a prospective longitudinal registry of cancer patients followed throughout the course of their illness. Dr. Batist was named a Knight of the National Order of Quebec and a Member of the Order of Canada in 2016.

Qualification

• MD
• FACP

After completion of her medical education in 1995, Dr. Hatoon Ezzat undertook additional studies in internal medicine and haematology. She is a fellow of the Royal College of Physicians and Surgeons of Canada and holds certifications in internal medicine and haematology from the American Board of Internal Medicine (ABIM). Her primary areas of interest in medicine are hemoglobinopathies, such as sickle-cell anaemia and thalassemia, and she actively participates in clinical research.

Qualification

• MBBS
• FRCPC
• ABIM

Oncologist and haematologist Dr. Sachi Voruganti is employed by Juravinski Cancer. One of Hamilton's top oncologists and haematologists is Dr. Voruganti. She investigates and makes diagnoses for illnesses and conditions affecting the immune system, bone marrow, and blood as a specialised oncologist and haematologist. In order to decide on the appropriate course of treatment, she consults with patients. Also, she advises and prescribes testing to establish the severity of the issue, aiding in the diagnosis.

Qualification

• MBBS
• DMRT
• MD
• MEd
• FRCPC

Oncologist and haematologist Dr. Hal Hirte is employed by Juravinski Cancer Center. One of Hamilton's top oncologists and haematologists is Dr. Hirte. He investigates and makes diagnoses for illnesses and conditions affecting the immune system, bone marrow, and blood as a committed oncologist and haematologist. In order to identify the appropriate course of treatment, he does this by speaking with patients. Also, he advises and prescribes testing to establish the severity of the ailment, aiding in the diagnosis. Many people today are afflicted with blood-related diseases and ailments. Hematologists and oncologists are used to treat these diseases.

Qualification

• MD
• FRCPC

Oncologist and haematologist Dr. Gordon Okawara is employed by Juravinski Cancer Center. One of Hamilton's top oncologists and haematologists is Dr. Okawara. He investigates and makes diagnoses for illnesses and conditions affecting the immune system, bone marrow, and blood as a committed oncologist and haematologist. In order to identify the appropriate course of treatment, he does this by speaking with patients. Also, he advises and prescribes testing to establish the severity of the ailment, aiding in the diagnosis.

Qualification

• MD